Track market-moving stories before they get noisy

--(BUSINESS WIRE)--UnitedHealthcare today announced a $540,000 investment to support Northeast Missouri Health Council (NMHC), a federally qualified health center, to help sustain and expand access to critical obstetrics and gynecology services (OB-GYN) for patients in rural communities. The support will help NMHC stabilize its current OB-GYN workforce, recruit additional maternal health providers, support development of an OB-GYN residency pathway and lay the groundwork for a rural family medi.

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.

The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.

It also includes access to the Zacks Style Scores.

What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.

Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.

The Style Scores are broken down into four categories:

Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.

Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.

Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.

VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.

How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.

It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +23.82% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.

That's where the Style Scores come in.

To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.

The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.

A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: UnitedHealth Group (UNH - Free Report) UnitedHealth Group provides a wide range of health care products and services, such as health maintenance organizations (HMOs), point-of-service plans (POS), preferred provider organizations (PPOs) and managed fee-for-service programs.

UNH is a #2 (Buy) on the Zacks Rank, with a VGM Score of A.

It also boasts a Value Style Score of A thanks to attractive valuation metrics like a forward P/E ratio of 20.27; value investors should take notice.

For fiscal 2026, 11 analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.75 to $20.57 per share. UNH boasts an average earnings surprise of +14%.

With a solid Zacks Rank and top-tier Value and VGM Style Scores, UNH should be on investors' short list.

UnitedHealth Group (UNH -0.54%) is showing signs of a comeback after a challenging stretch, with earnings rising sharply in its latest report as its turnaround gains momentum. Still, whether investors should add shares, trim them, or sit tight comes down to one question: Can the company continue with its earnings recovery?

Image source: Getty Images.

UnitedHealth's earnings rebound is gaining momentum In the third quarter of 2026, adjusted earnings per share climbed around 61% from a year earlier, beating Wall Street expectations. Revenue also came in ahead of forecasts, while management raised its full-year adjusted earnings guidance to at least $20.50 per share. That's an improvement from its previous forecast of $19.50 to $20.00.

The encouraging part is that UnitedHealth isn't relying on revenue growth to improve its bottom line. Instead, it's working to price its insurance plans more carefully, control medical expenses, and streamline operations. These changes are helping it generate more profit from its existing business.

For investors who have been waiting for signs of a strong recovery, this is a meaningful step in the right direction. In fact, UnitedHealth's latest results are proof that its turnaround is picking up.

What's behind the improvement?

Better control over medical costs is driving recovery One of UnitedHealth's biggest challenges has been the rising cost of providing healthcare to its members. When patients use more medical services than expected, the company can end up paying out more in claims than its premiums were designed to cover.

That makes the latest improvement in its medical care ratio encouraging. The ratio fell to 88.4% compared with 89.9% a year earlier. That means the company spent a smaller share of its insurance premiums on medical care, leaving more room for profit.

Management says the improvement came from more disciplined pricing, changes to insurance benefits, and better medical cost management. The company has also adjusted its product offerings rather than expanding into areas that may not generate attractive returns.

If UnitedHealth can better match its premiums to the actual cost of care, it should be in a better position to expand margins and grow earnings over time. But the insurance business isn't the only part of the company worth watching.

Optum is showing signs of a turnaround UnitedHealth's Optum division provides healthcare services and pharmacy benefits, giving the company more ways to participate in the healthcare industry. In the past, Optum Health faced challenges around costs and operations.

But the latest results showed a huge improvement. Optum Health's operating earnings reached $735 million, up from just $41 million in the same period last year.

The opportunity here is significant. If Optum can continue improving profitability, it could become an important contributor to UnitedHealth's broader earnings recovery.

With both businesses improving, the next question is what that means for the stock.

UNH UnitedHealth Group$417.00-$2.26 (-0.54%)

NYSE · As of 4:00 PM ET 10/21/26

Is UnitedHealth stock worth buying after its latest earnings? Wall Street analysts are bullish on the stock, with a consensus Strong Buy rating based on 26 analysts. Their target prices, meanwhile, are rather wide. Analysts expect UnitedHealth stock to trade between $380 and $529 per share over the next year, implying up to 32% upside. But with the stock trading at a price-to-earnings (P/E) ratio of about 23, the stock isn't exactly dirt cheap. Of course, investors today wouldn't be paying a premium either.

That said, UnitedHealth still has more work to do to make this recovery sustainable.

Membership has declined as the company cuts back on exposure to certain insurance plans and less profitable markets. Meanwhile, medical costs and stricter regulations could put pressure on future margins.

Those risks are real, but the company's efforts to improve margins are showing promising results. If UnitedHealth can sustain its earnings recovery, the stock could still have room to run.

The turnaround has strengthened the bull case for UnitedHealth. For patient investors, the comeback could be a reason to hold or add shares rather than sell, with further upside possible if earnings continue to recover.

I'm initiating coverage of UnitedHealth Group with a Strong Buy rating and a $533 price target, implying 33% upside potential. I believe UNH margin recovery, Optum Health's shift toward higher-quality contracts, and AI-driven operating efficiencies can support double-digit EPS growth through 2028. UNH trades at a forward non-GAAP PEG ratio of 1.38x, approximately 26% below the healthcare sector median of 1.87x.

Maia Wealth LLC raised its holdings in UnitedHealth Group Incorporated (NYSE: UNH) by 17.7% during the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 14,252 shares of the healthcare conglomerate's stock after purchasing an additional 2,148 shares during the quarter. Maia Wealth

Key Takeaways UnitedHealth's Q3 adjusted EPS beat estimates by 13.8%, while revenues exceeded expectations by 1.2%.UnitedHealth raised its 2026 adjusted EPS guidance to at least $20.50 despite elevated commercial costs.ETFs like IHF offer diversified healthcare exposure, with UnitedHealth weightings ranging more than 4%.
Shares of UnitedHealth Group Incorporated (UNH - Free Report) have jumped 6.3% on the bourses since the company released better-than-expected third-quarter 2026 results on Oct. 13. The healthcare service provider's quarterly figures showed strong financial execution and operational recovery, even as underlying headwinds persisted in the form of membership losses and elevated commercial costs.

The company’s chief financial officer Wayne DeVeydt raised 2026 adjusted earnings guidance to at least $20.50 per share, setting a stronger earnings base heading into 2027.

Given this upbeat outlook, investors may want to invest in America’s largest health insurer right away. However, given the current U.S. government's legislation last year, which includes major Medicaid funding cuts this year, UNH’s Medicaid business is likely to face significant downward margin pressure. To this end, UNH’s management continues to view 2026 as a trough year for core Medicaid margins. 

Against this backdrop, prudent investors may be drawn to diversified healthcare exchange-traded funds (ETFs) with significant exposure to UNH, alongside other healthcare giants across pharma, biotech and medtech, as a more strategic investment choice. This would help investors gain from UNH’s upbeat outlook this year while avoiding the risks associated with its Medicaid business. 

Before suggesting a few such ETFs for your portfolio, let’s take a detailed look at UnitedHealth’s third-quarter performance across key metrics and provide a brief outlook on what to expect in the coming months.

A Brief Analysis of UNH’s Q3 ResultsUnitedHealth’s third-quarter adjusted earnings per share (EPS) of $4.69 beat the Zacks Consensus Estimate by 13.8%, while its revenues beat the consensus mark by 1.2%. 

On a year-over-year basis, the company delivered a mixed performance. Its earnings improved 60.6%, but revenues slipped 0.4%. 
UNH’s adjusted medical care ratio (MCR) was 88.4% in the third quarter, which improved 150 basis points (bps) from the year-ago period.

The improvement reflects better medical cost management, benefit and pricing alignment, and care delivery enhancements.
Its operating cost ratio improved 70 bps year over year to 12.8% in the quarter, backed by ongoing investments to modernize operations and streamline administrative processes. 

In its Optum Health business, UNH delivered strong performance in the third quarter, driven by the continued return to value-based care principles, combined with strong execution across its clinical programs and operational improvements, enabling clinicians to focus more on their patients and improve patient experience.

As for UNH’s commercial business, the company witnessed stable performance in the third quarter despite a tough market. However, UNH continues to experience higher-than-expected costs for this business, owing to a small number of doctors abusing the dispute process under the No Surprises Act (as mentioned in its third-quarter transcript), in addition to rising costs for specialty drugs and clinician care. 

UNH expects to pay more than $8 billion in dividends by 2026-end. 

Meanwhile, to make patient care faster and easier, the company is simplifying its prior approval process by cutting paperwork, increasing transparency and standardizing requirements across the industry. By the end of 2026, UNH plans to eliminate 30% of overall approval requirements, including nearly two-thirds of those for pediatric care and 10% from home health services, while expanding its "Gold Card" program to completely exempt top-performing doctors from routine approvals. 

Additionally, more than 70% of remaining approvals will be streamlined through standardized electronic submissions, and performance metrics will be published publicly to keep clinicians and members informed. 

Analysts’ ReactionFollowing UNH’s third-quarter results, Barclays analyst Andrew Mok maintained an Overweight rating but cut the stock’s price target from $441 to $440. Baird analyst Michael Ha maintained a Neutral rating and lowered the price target from $453 to $427.

UNH-Heavy ETFs to Watch

iShares U.S. Healthcare Providers ETF (IHF - Free Report)

This fund, with net assets worth $1.40 billion, offers exposure to 61 U.S. companies in the healthcare providers subsector, including insurers and service operators. UNH holds the first spot in this fund, with a 22.22% weight. 

IHF jumped 22.4% year to date and charges 37 bps in fees. It traded at a good volume of 3.21 million shares in the last trading session and holds a Zacks ETF Rank #2 (Buy). 

State Street Health Care Select Sector SPDR ETF (XLV - Free Report)

This fund, with assets under management (AUM) worth $46.19 billion, includes 61 companies in the pharmaceuticals; health care equipment and supplies; health care providers and services; biotechnology; life sciences tools and services; and health care technology industries. UNH holds the fourth spot in this fund, with a 5.68% weight. 

XLV rose 14.2% year to date and charges 8 bps in fees. It traded at a good volume of 8.55 million shares in the last trading session and sports a Zacks ETF Rank #1 (Strong Buy). 

Vanguard Health Care Index Fund ETF (VHT - Free Report)

This fund, with net assets worth $21.8 billion, is exposed to companies that manufacture health care equipment and supplies or that provide health care-related services, and firms that are primarily involved in the research, development, production and marketing of pharmaceuticals and biotechnology products. UNH holds the fifth spot in this fund, with a 4.65% weight. 

VHT soared 13.7% year to date and charges 9 bps in fees. It traded at a volume of 0.25 million shares in the last trading session and sports a Zacks ETF Rank #1. 

The past few years have been challenging ones for health insurance giant UnitedHealth Group (UNH -1.29%). Rising costs have been weighing on its results, and its five-year returns are in the red, with the stock declining by more than 5% during that stretch. That's unusual for a stock that historically has generated terrific returns for investors.

The company, however, has been showing progress in recent earnings reports and in its latest one, once again showed improvements in its bottom line. The healthcare stock itself has also been picking up steam this year, as it's up around 22% thus far in 2026. With another strong quarter in the books, has UnitedHealth Group done enough to prove that it's a good buy again?

Image source: Getty Images.

UnitedHealth exceeded expectations in Q3Last week, UnitedHealth posted earnings that didn't simply beat expectations; they soared past them. Its revenue for the quarter ending Sept. 30 totaled $112.7 billion, which was down from the prior-year period ($113.2 billion) but far higher than what analysts expected -- $111.4 billion. Its adjusted earnings per share (EPS) of $4.69 was also higher than Wall Street's expectations of $4.14.

In light of its improved results, the healthcare company also raised its guidance slightly, now expecting adjusted EPS to be at least $20.50 for the year, which is higher than its previous guidance, which ranged from $19.50 to $20. UnitedHealth has been able to achieve efficiencies by exiting markets that were unprofitable and also investing in artificial intelligence (AI).

$401.43-$5.24 (-1.29%)

NYSE · As of 4:00 PM ET 10/16/26

Is UnitedHealth stock a cheap buy?UnitedHealth stock closed at just over $401 last week as it gained momentum amid its strong earnings numbers. Given its sluggish performance in recent years, the stock remains fairly cheap with respect to earnings. Its forward price-to-earnings multiple is around 16, which is based on the level of profitability analysts project from the business in the year ahead. By comparison, the average S&P 500 stock trades at more than 19 times its estimated future profits.

For investors, it appears that UnitedHealth Group can still be an excellent long-term buy given its modest valuation and strong earnings results. It's been heading in the right direction for multiple quarters, and it also offers an above-average dividend that yields 2.3%, making it an attractive option for income investors seeking a reliable payout.

Overall, UnitedHealth is a compelling option for investors seeking value, stability, and dividend income.

Annex Advisory Services LLC grew its holdings in UnitedHealth Group Incorporated (NYSE:UNH – Free Report) by 70.4% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 116,856 shares of the healthcare conglomerate’s stock after purchasing an additional 48,279 shares during the period. Annex Advisory Services LLC’s holdings in UnitedHealth Group were worth $42,896,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the business. North Capital Inc. bought a new stake in UnitedHealth Group in the third quarter worth $210,000. Milestone Asset Management LLC lifted its position in shares of UnitedHealth Group by 14.4% in the third quarter. Milestone Asset Management LLC now owns 12,480 shares of the healthcare conglomerate’s stock worth $4,581,000 after buying an additional 1,570 shares during the last quarter. Detalus Advisors LLC acquired a new position in shares of UnitedHealth Group during the 3rd quarter valued at about $431,000. SLT Holdings LLC increased its holdings in shares of UnitedHealth Group by 6.1% during the 3rd quarter. SLT Holdings LLC now owns 7,328 shares of the healthcare conglomerate’s stock valued at $2,690,000 after acquiring an additional 419 shares during the last quarter. Finally, Whitener Capital Management Inc. boosted its position in UnitedHealth Group by 14.9% during the third quarter. Whitener Capital Management Inc. now owns 4,475 shares of the healthcare conglomerate’s stock worth $1,643,000 after purchasing an additional 582 shares during the period. Hedge funds and other institutional investors own 87.86% of the company’s stock.

Insider Buying and Selling at UnitedHealth Group In other news, CEO Patrick Conway sold 1,169 shares of the company’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $390.00, for a total transaction of $455,910.00. Following the transaction, the chief executive officer owned 15,328 shares of the company’s stock, valued at $5,977,920. This represents a 7.09% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.19% of the stock is currently owned by insiders.

UnitedHealth Group News Roundup Here are the key news stories impacting UnitedHealth Group this week: Positive Sentiment: Q3 results and guidance exceeded expectations. UnitedHealth reported adjusted earnings of $4.69 per share versus the $4.14 consensus estimate, while revenue of $112.7 billion also topped forecasts. Management raised its 2026 adjusted EPS outlook to at least $20.50, supporting the recovery narrative. UnitedHealth Stock Moves Higher: What’s Going On? Positive Sentiment: Analyst support remains significant. JPMorgan raised its price target to $524 and maintained an “overweight” rating, while Goldman Sachs reportedly lifted its target to $506 after concluding that Medicare Advantage margin recovery is progressing faster than expected. JPMorgan Raises UnitedHealth Price Target Positive Sentiment: Potential growth areas could support 2027 and beyond. UnitedHealth’s focus on Medicare special-needs plans, expanded coverage and care-delivery operations may provide targeted growth while improving margins. Its low beta also makes UNH attractive as a defensive healthcare holding during inflation and market rotation away from technology stocks. Can UNH’s Focus on Special Needs Plans Strengthen Medicare Growth? Neutral Sentiment: Recent gains may have already priced in much of the good news. Commentary noted that the earnings beat and outlook increase were followed by questions about how durable the recovery will be, limiting the immediate upside despite bullish targets. UnitedHealth Beats on Earnings, But Investors Question Growth Path Negative Sentiment: Membership fell and medical costs remain high. Analysts are concerned that shrinking membership and elevated utilization could constrain revenue growth and margins, particularly if higher care costs persist. This is the main reason investors are questioning whether the earnings improvement can continue. UnitedHealth’s Q3 Margins Improve, But Membership Falls Negative Sentiment: Analyst views are mixed. Barclays issued a pessimistic forecast, Robert W. Baird cut its price target, and TD Cowen reiterated a “hold” rating with a $402 target, signaling limited near-term upside for some investors. UnitedHealth Group Price Performance Shares of UNH stock opened at $401.77 on Friday. The stock’s fifty day moving average is $387.07 and its 200-day moving average is $384.64. The stock has a market capitalization of $360.62 billion, a PE ratio of 19.92, a PEG ratio of 1.47 and a beta of 0.60. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.78 and a current ratio of 0.74. UnitedHealth Group Incorporated has a 52 week low of $255.96 and a 52 week high of $461.62.

UnitedHealth Group (NYSE:UNH – Get Free Report) last issued its quarterly earnings data on Tuesday, October 13th. The healthcare conglomerate reported $4.69 EPS for the quarter, topping analysts’ consensus estimates of $4.14 by $0.55. UnitedHealth Group had a net margin of 3.53% and a return on equity of 17.95%. The firm had revenue of $112.70 billion for the quarter, compared to analyst estimates of $111.31 billion. During the same quarter in the prior year, the firm earned $2.59 EPS. The company’s revenue was down .4% on a year-over-year basis. UnitedHealth Group has set its FY 2026 guidance at 20.500- EPS. Equities research analysts expect that UnitedHealth Group Incorporated will post 20.65 EPS for the current fiscal year.

UnitedHealth Group Announces Dividend The company also recently announced a quarterly dividend, which was paid on Tuesday, September 22nd. Stockholders of record on Monday, September 14th were paid a $2.32 dividend. This represents a $9.28 annualized dividend and a dividend yield of 2.3%. The ex-dividend date of this dividend was Monday, September 14th. UnitedHealth Group’s dividend payout ratio (DPR) is 53.00%.

Analysts Set New Price Targets A number of analysts have recently weighed in on the stock. The Goldman Sachs Group boosted their price objective on shares of UnitedHealth Group from $435.00 to $490.00 and gave the stock a “buy” rating in a research note on Friday, July 17th. Evercore raised their target price on shares of UnitedHealth Group from $400.00 to $480.00 and gave the company an “outperform” rating in a research note on Tuesday, July 7th. Mizuho boosted their target price on shares of UnitedHealth Group from $470.00 to $493.00 and gave the stock an “outperform” rating in a research report on Monday, July 20th. Robert W. Baird decreased their price target on shares of UnitedHealth Group from $453.00 to $427.00 and set a “neutral” rating for the company in a report on Wednesday. Finally, Oppenheimer lifted their price objective on UnitedHealth Group from $420.00 to $500.00 and gave the stock an “outperform” rating in a research note on Friday, July 17th. Twenty equities research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $462.90.

Read Our Latest Analysis on UNH

UnitedHealth Group Company Profile (Free Report)

UnitedHealth Group Incorporated (NYSE: UNH) is a diversified health care and well-being company serving individuals, employers, health care providers and government programs. Its operations are organized primarily through UnitedHealthcare and Optum.

UnitedHealthcare provides health benefit plans and services, including employer-sponsored coverage, individual and family plans, Medicare and Medicaid offerings, and other government-supported programs. Its services include health insurance administration, pharmacy benefits and care management.

Optum provides health care services, technology and data solutions, pharmacy services, and analytics to health plans, employers, government agencies, health care providers and consumers.

Further Reading Five stocks we like better than UnitedHealth Group Bank of America Stock Sell-Off Looks Like a Buying Opportunity AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff? GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out? Want to see what other hedge funds are holding UNH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for UnitedHealth Group Incorporated (NYSE:UNH – Free Report).

Receive News & Ratings for UnitedHealth Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group and related companies with MarketBeat.com's FREE daily email newsletter.

Broadcom and other companies have objected to tokenizing their shares under a new regulatory framework.

Assenagon Asset Management S.A. trimmed its position in shares of UnitedHealth Group Incorporated (NYSE:UNH – Free Report) by 34.6% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 853,517 shares of the healthcare conglomerate’s stock after selling 452,536 shares during the period. Assenagon Asset Management S.A. owned 0.10% of UnitedHealth Group worth $313,309,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Corient Private Wealth LP purchased a new position in UnitedHealth Group in the 2nd quarter worth approximately $245,516,000. Legal & General Group Plc bought a new stake in UnitedHealth Group in the 2nd quarter valued at $2,444,928,000. Jupiter Topco LLC purchased a new stake in UnitedHealth Group in the 2nd quarter worth $2,019,844,000. BlackRock Inc. boosted its holdings in shares of UnitedHealth Group by 4.6% during the 2nd quarter. BlackRock Inc. now owns 76,863,061 shares of the healthcare conglomerate’s stock valued at $31,946,594,000 after purchasing an additional 3,395,530 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. grew its position in shares of UnitedHealth Group by 141.9% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 4,109,029 shares of the healthcare conglomerate’s stock valued at $1,356,432,000 after purchasing an additional 2,410,128 shares in the last quarter. Hedge funds and other institutional investors own 87.86% of the company’s stock.

UnitedHealth Group News Summary Here are the key news stories impacting UnitedHealth Group this week:

Positive Sentiment: Q3 earnings beat expectations: UnitedHealth reported adjusted EPS of $4.69 versus the $4.14 consensus estimate and revenue of $112.7 billion versus $111.31 billion expected. Revenue was roughly flat year over year, but profitability improved significantly. UnitedHealth Stock Moves Higher: What’s Going On? Positive Sentiment: Higher earnings outlook: Management raised its 2026 adjusted earnings forecast to at least $20.50 per share, above its previous $19.50–$20.00 range. The guidance increase was the primary catalyst for the stock’s upward move. UnitedHealth Group gains after Q3 beat and higher 2026 outlook Positive Sentiment: Margin recovery signals: The medical care ratio improved to 88.4%, while Optum generated $3.7 billion in earnings. Analysts also cited pricing discipline, benefit changes, care-delivery improvements and AI initiatives as potential supports for stronger 2027 growth. UNH Q3 Deep Dive: Margin Recovery and AI Initiatives Shape 2027 Outlook Positive Sentiment: Constructive analyst views: Goldman Sachs reportedly raised its price target to $506, while Piper Sandler maintained an overweight rating and lifted its target to $504. Mizuho also continues to view UNH as a top healthcare pick. Goldman Sachs raises UNH target price to $506 Neutral Sentiment: Defensive appeal: UnitedHealth is being highlighted as a low-beta healthcare stock that could benefit from investor demand for defensive companies if inflation and energy costs remain elevated. 3 Low-Beta Defensive Stocks to Buy as Inflation Continues to Surge Negative Sentiment: Growth risks remain: Analysts flagged shrinking membership, pressure from commercial medical costs and Medicaid, and uncertainty surrounding Medicare participation. TD Cowen reaffirmed a hold rating with a $402 target, while other firms reduced targets despite maintaining generally positive ratings. UnitedHealth Beats on Earnings, But Investors Question Growth Path Insider Buying and Selling In other UnitedHealth Group news, CEO Patrick Conway sold 1,169 shares of the business’s stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $390.00, for a total transaction of $455,910.00. Following the sale, the chief executive officer owned 15,328 shares of the company’s stock, valued at approximately $5,977,920. The trade was a 7.09% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.19% of the stock is owned by company insiders. UnitedHealth Group Price Performance UNH opened at $407.45 on Friday. The company has a current ratio of 0.74, a quick ratio of 0.78 and a debt-to-equity ratio of 0.66. The business’s fifty day simple moving average is $387.17 and its 200-day simple moving average is $384.52. The company has a market capitalization of $365.72 billion, a price-to-earnings ratio of 19.38, a PEG ratio of 1.43 and a beta of 0.60. UnitedHealth Group Incorporated has a 12-month low of $255.96 and a 12-month high of $461.62.

UnitedHealth Group (NYSE:UNH – Get Free Report) last posted its earnings results on Tuesday, October 13th. The healthcare conglomerate reported $4.69 EPS for the quarter, beating analysts’ consensus estimates of $4.14 by $0.55. The business had revenue of $112.70 billion for the quarter, compared to the consensus estimate of $111.31 billion. UnitedHealth Group had a net margin of 3.53% and a return on equity of 17.95%. The company’s revenue for the quarter was down .4% on a year-over-year basis. During the same quarter last year, the firm posted $2.59 EPS. UnitedHealth Group has set its FY 2026 guidance at 20.500- EPS. On average, equities research analysts anticipate that UnitedHealth Group Incorporated will post 20.66 earnings per share for the current fiscal year.

UnitedHealth Group Announces Dividend The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 22nd. Investors of record on Monday, September 14th were given a dividend of $2.32 per share. This represents a $9.28 annualized dividend and a yield of 2.3%. The ex-dividend date of this dividend was Monday, September 14th. UnitedHealth Group’s dividend payout ratio is currently 59.72%.

Wall Street Analyst Weigh In A number of equities analysts recently commented on the company. Bank of America reissued a “buy” rating and set a $450.00 price target on shares of UnitedHealth Group in a research note on Monday, July 20th. TD Cowen reaffirmed a “hold” rating and set a $402.00 price objective on shares of UnitedHealth Group in a report on Thursday. Oppenheimer increased their target price on UnitedHealth Group from $420.00 to $500.00 and gave the company an “outperform” rating in a research report on Friday, July 17th. HSBC raised their target price on shares of UnitedHealth Group from $300.00 to $380.00 and gave the company a “hold” rating in a report on Monday, July 6th. Finally, Jefferies Financial Group boosted their price objective on shares of UnitedHealth Group from $401.00 to $490.00 and gave the company a “buy” rating in a research report on Friday, July 17th. Twenty analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $461.48.

Check Out Our Latest Research Report on UNH

(Free Report)

UnitedHealth Group Incorporated (NYSE: UNH) is a diversified health care and well-being company serving individuals, employers, health care providers and government programs. Its operations are organized primarily through UnitedHealthcare and Optum.

UnitedHealthcare provides health benefit plans and services, including employer-sponsored coverage, individual and family plans, Medicare and Medicaid offerings, and other government-supported programs. Its services include health insurance administration, pharmacy benefits and care management.

Optum provides health care services, technology and data solutions, pharmacy services, and analytics to health plans, employers, government agencies, health care providers and consumers.

See Also Five stocks we like better than UnitedHealth Group ASML Can’t Keep Up With AI Demand—Why That’s a Good Thing Enovix’s 100,000-Battery Drone Order Sets Up a Test of Its Production Plans AMD’s Support Could Help Fermi Stock Overcome Its Biggest Hurdle Beyond the GPU: Credo Paves the Next AI Data Superhighway Want to see what other hedge funds are holding UNH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for UnitedHealth Group Incorporated (NYSE:UNH – Free Report).

Receive News & Ratings for UnitedHealth Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group and related companies with MarketBeat.com's FREE daily email newsletter.

UnitedHealth's wild ride inside DIA was not an accident or a manager's call. The weighting rule baked into the Dow determined exactly how much of your money followed the stock up and down, and most investors have never read that…

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

On November 11, 2024, UnitedHealth Group (NYSE:UNH | UNH Price Prediction) traded at $596.08. By May 30, 2025, it had fallen to $290.17, a 51.32% decline on a dividend-adjusted basis. From that bottom through October 15, 2026, the stock rose 40.64%. A delayed intraday quote on October 15, 2026, put it at $408.08, still below the November 2024 peak. If you own SPDR Dow Jones Industrial Average ETF (NYSEARCA:DIA), UnitedHealth’s share of your fund shrank and swelled along that entire path, driven solely by its share price.

Share Price Alone Sets Your Stake State Street Global Advisors describes DIA’s benchmark as a price-weighted index of 30 component common stocks. Price-weighted means one simple rule: the higher a stock’s share price, the bigger its slice of the fund. Company size, earnings, and business quality play no role.

As UnitedHealth’s share price fell by half, its influence inside DIA fell with it. As the price climbed back, that influence returned automatically. The fund holds the most of a stock when it is most expensive and the least when it is cheapest. Those shifts come from the weighting rule alone.

The relationship above follows directly from the published weighting method.

Where Your Money Sits Right Now State Street Global Advisors reports UnitedHealth at 4.55% of DIA as of October 14, 2026, making it the fund’s fifth-largest holding. State Street Global Advisors lists Goldman Sachs (NYSE:GS) as the largest position at 10.11% on the same date. Caterpillar (NYSE:CAT) ranks second at 8.62% and Microsoft (NASDAQ:MSFT) third at 6.14%.  The fourth-largest holding sits at 4.90%.

Goldman leads because, under price weighting, the top position is by definition the highest-priced stock. That ranking reflects what one share costs. It says nothing about which business is largest or best run. These weights move every trading day with share prices.

Same Rule Cushioned the Fall The rule that returned UnitedHealth’s role in the rebound also trimmed it on the way down. While the stock slipped from $596.08 to $290.17, DIA’s shrinking position limited the damage compared with a fund holding a fixed percentage. Price weighting cuts exposure to losers and adds exposure to risers. That helps in a sustained decline and hurts in a sharp rebound. Which effect wins depends entirely on the path a stock takes.

The method has real strengths, too. The Dow carries an extremely long history, DIA is large and widely held, the methodology is published, and professionals understand it. No single holding wins the fund, so the effect on any one name stays limited.

Fee Gap You Pay Every Year State Street Global Advisors lists DIA’s gross expense ratio at 0.16%, or $16 a year per $10,000 invested. Broad S&P 500 index funds charge as little as 0.03%, about $3 per $10,000. That gap compounds quietly, but it matters less than how the fund decides what you own.

Two Other Ways to Set Weights A market-cap-weighted fund sizes positions by total company value (share price times shares outstanding), which at least tracks something economic about the business. An equal-weight fund resets every holding to the same slice on a schedule, buying more of whatever has fallen. Price weighting instead follows the number printed on a single share, a number a stock split can cut overnight with no change to the underlying company.

What Every DIA Holder Should Understand If you own DIA because the Dow sounds safe, note that, per State Street Global Advisors, share price alone determines how your money is allocated among its 30 stocks. UnitedHealth’s plunge and partial recovery show how that plays out on a real holding. Before you assume any fund’s largest positions reflect conviction or company size, check its weighting method. That single line in the prospectus tells you what is picking your stocks.

Contact [email protected] for any questions or corrections.

Key Takeaways UNH is prioritizing C-SNPs and D-SNPs for 2027 to drive targeted Medicare Advantage growth.C-SNPs will reach nearly 50M Medicare-eligible individuals, while D-SNPs will cover 74% of dual eligibles.UNH expects Medicare margins near the upper end of its 2%-4% target in 2026, aided by better cost management. UnitedHealth Group Incorporated (UNH - Free Report) is refining its Medicare Advantage strategy, emphasizing high-value health maintenance organization (HMO) plans and specialized coverage for seniors with complex healthcare needs. For 2027, UnitedHealthcare plans to prioritize Chronic Special Needs Plans (C-SNPs) and Dual Eligible Special Needs Plans (D-SNPs).

The opportunity is substantial. UnitedHealthcare's C-SNPs will be available to nearly 50 million Medicare-eligible individuals in 2027, offering tailored support for people managing conditions such as diabetes, cardiovascular disease and chronic heart failure. Meanwhile, its D-SNPs will reach approximately 74% of dual-eligible individuals, facilitating coordinated Medicare and Medicaid benefits. These plans can connect members with more coordinated care, medication support and preventive services, potentially creating opportunities to improve outcomes and limit avoidable healthcare spending.

UNH's approach also fits its broader shift toward more selective Medicare Advantage offerings. The company is adjusting plan benefits and market participation to better align coverage with healthcare costs. It expects Medicare margins to approach the upper end of its 2%-4% target range in 2026, reflecting improved cost management and product positioning. Integrated care through Optum Health could further support this strategy by coordinating services for members with complex needs.

Star ratings remain another consideration. UnitedHealthcare reported that at least 69% of its Medicare Advantage members are in plans rated four stars or higher for 2027. UNH's focus on special needs plans could support targeted growth, but execution, medical costs and quality performance can shape the results.

How Are Competitors Faring?Some of UNH’s major competitors in the healthcare service provider space are Humana Inc. (HUM - Free Report) and Centene Corporation (CNC - Free Report) .

Humana is expanding its Chronic Condition Special Needs Plans into Pennsylvania, Utah and Wisconsin for 2027. HUM’s focus on tailored coverage and coordinated care could attract beneficiaries with complex conditions, while stronger Star Ratings may support its Medicare Advantage competitiveness.

Through its Wellcare brand, Centene is emphasizing affordable Medicare Advantage coverage and integrated care for dual-eligible beneficiaries in 2027. CNC’s coordinated Medicare-Medicaid offerings could strengthen its appeal among members with complex needs, although managing medical expenses remains key.

UnitedHealth’s Price Performance, Valuation & EstimatesShares of UNH have gained 19.5% in the year-to-date period compared with the industry’s rise of 22.9%.

Image Source: Zacks Investment Research

From a valuation standpoint, UnitedHealth trades at a forward price-to-earnings ratio of 18, above the industry average of 15.73. UNH carries a Value Score of A.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for UnitedHealth’s 2026 earnings is pegged at $19.85 per share, implying 21.4% growth from the year-ago period.

Image Source: Zacks Investment Research

UNH stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

UnitedHealth Group Today

UNH

UnitedHealth Group

$396.02 +18.26 (+4.83%)

As of 10/14/2026 03:59 PM Eastern

This is a fair market value price provided by Massive. Learn more.

$255.96▼

$461.622.34%

22.62

$461.83

For the third consecutive quarter, UnitedHealth Group NYSE: UNH delivered a beat on both its top and bottom lines. But, as with the company’s Q2 2026 report, investors gave the news a lukewarm response. UNH shares opened about 5% higher and touched $399.88. By mid-afternoon, they had given back all their gains and slipped below their 50-day moving average.

UNH is down sharply since reaching a 52-week high in July. The earnings report showed that UnitedHealth Group’s turnaround is going well. But with the easy comps in the past, investors are wondering where the growth will come from.

Get UnitedHealth Group alerts:

The Report Reinforced the Turnaround StoryIn Q3 2026, revenue came in at $112.7 billion, topping expectations, but it was slightly below the $113.2 billion UNH reported a year ago. That decline is by design, and it’s central to understanding this quarter. UNH is shedding members and markets that don’t meet its profit targets.

On the earnings front, the news was even better. This was the fourth consecutive quarter in which UnitedHealth beat expectations for adjusted earnings per share (EPS). Adjusted EPS of $4.69 jumped 61% year over year (YOY). The company also raised its full-year adjusted EPS outlook to at least $20.50, a 25% YOY increase.

But the headline results from the earnings report require context. That context helps explain the lukewarm post-earnings reaction.

A Simpler, More Supportive ModelIf investors want to understand UnitedHealth’s Q3 earnings report, they should pay close attention to this statement from CEO Stephen Hemsley:

“Our third quarter results reflect the discipline and execution our teams are bringing to every part of our business, as we continue evolving UnitedHealth Group to deliver a simpler, more supportive experience for patients and the clinicians who care for them.”

In practice, simpler means smaller. UnitedHealthcare served 48.3 million people at the end of September, down from 50.1 million a year earlier. Much of this is deliberate. Medicare Advantage, Medicaid, and risk-based commercial membership each fell about 10%. UNH closed more than 100 Medicare Advantage plans for 2026, covering about 600,000 members. Others left after facing higher costs or thinner benefits.

The payoff shows up in the margins. The medical care ratio, the share of premiums spent on care, fell to 88.4% from 89.9%. UnitedHealthcare’s operating margin rose to 3.3% from 2.1%. Optum Health’s margin climbed to 3.2% from just 0.2%, even as its revenue fell 10%. One caveat: the quarter included $610 million of favorable reserve development, worth roughly 0.7 points on that ratio.

Is the Dividend Enough?The dividend is an attractive selling point for UNH. The yield of 2.4% isn’t particularly impressive. However, it pays $9.28 per share annually, which is an attractive payout for income-seeking investors. Cash flow supports that payout. Operating cash flow reached $25.1 billion through nine months, up from $18.6 billion a year ago.

It also explains why the stock has rallied hard since closing at a low of around $257 in late March. Healthcare has been a logical choice for investors looking for alternatives outside the technology/AI trade. At 19x forward earnings, UNH also trades at a nice value compared to its history and the broader market.

But a long-term buy-and-hold investment requires some growth, and getting a bit smaller and more selective doesn’t count as growth. At least it doesn’t count in a sustainable way.

Revenue is up just 0.6% through nine months. And the shrinkage isn’t finished. About 390,000 members are in plans to be discontinued for 2027.

Bulls have a fair counterpoint. Margin recovery alone could lift 2027 earnings. The question is how much recovery remains. Investors may get a clearer answer in January, when UNH typically issues its outlook for the year ahead.

The Long-Term Case Remains IntactStill, UnitedHealth remains one of the best names in the healthcare sector. The 12-month growth in UNH is a testament to that.

This may be a case where investors weren’t wrong, just early. If that’s true, the consensus price target of $462.59, which implies about 18% upside, looks very attractive. But there may be some bumps along the way.

UnitedHealth Group Incorporated (UNH) Price Chart for Thursday, October, 15, 2026

Those bumps are already visible on the chart. Since July, UNH has made lower highs and lower lows. The rising 200-day moving average at $358 is the key support. A move above $400 would challenge the downtrend. A break below $365 would confirm it. Volume is worth watching in the days ahead, since it shows how much conviction sits behind the selling.

Should You Invest $1,000 in UnitedHealth Group Right Now?Before you consider UnitedHealth Group, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and UnitedHealth Group wasn't on the list.

While UnitedHealth Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

What happened UnitedHealth Group (NYSE: UNH) reported third quarter 2026 results and raised full-year 2026 adjusted earnings guidance on October 13, 2026. Consolidated revenues were $112.7 billion. Earnings from operations were $6.6 billion. Net margin was 3.6%.

Diluted earnings were $4.56 per share. Adjusted earnings were $4.69 per share. The company now expects full-year 2026 adjusted net earnings of at least $20.50 per share. UnitedHealthcare served 48.3 million consumers and generated $86.3 billion of revenue. Optum cared for over 120 million patients and consumers and drove $66.9 billion of revenue.

Key numbers Metric Latest Change Source Third quarter 2026 revenues $112.7 billion from $113.2 billion, -$0.5 billion SEC 8-K Third quarter 2026 earnings from operations $6.6 billion from $4.3 billion, + $2.3 billion SEC 8-K Third quarter 2026 net margin 3.6% from 2.1%, +1.5 percentage points SEC 8-K Third quarter 2026 adjusted earnings per share $4.69 per share from $2.92 per share, + $1.77 per share SEC 8-K Cash flows from operations $5.1 billion SEC 8-K Full-year 2026 adjusted net earnings outlook At least $20.50 per share SEC 8-K Read more: UnitedHealth Group (UNH) stock analysis and investment case Why it matters Cash flows from operations were $5.1 billion, or 1.2x net income. The debt-to-capital ratio was 41.7% as of September 30, 2026. Operating earnings rose $2.3 billion from $4.3 billion a year earlier. The operating cost ratio was 12.8%, compared with 13.5% in the third quarter 2025. MCR was 88.4% and included $610 million of net favorable prior period reserve development related to 2026 dates of service.

OptimistFi's case is that UnitedHealth's scale still turns revenue into cash and shareholder returns, and the raised outlook supports that view. The caveat is that Optum Health revenues of $22.9 billion decreased 10% year-over-year. That keeps the normalization question open for the services business. UnitedHealthcare earnings from operations were $2.8 billion, and Optum earnings from operations were $3.7 billion.

UnitedHealthcare revenues were $86.3 billion, while Optum revenues were $66.9 billion, keeping both businesses central to the quarter. The company repurchased $5.0 billion of common stock and paid $6.2 billion in dividends year-to-date.

Browse: stock research on every company OptimistFi covers

What's next UnitedHealth Group will discuss the results, strategy and future outlook on a conference call with investors at 8:00 a.m. Eastern Time today. The webcast replay will remain on the Investor Relations page through October 27, 2026. Clearer signs that medical costs and Optum Health are stabilizing would strengthen the case, while further pressure there would weaken it.

More from OptimistFi UNH stock: the UnitedHealth Group thesis, its status and the next test to watch Meta Platforms, Inc. (NASDAQ: META) Prices Muse Wonder for Developers American Superconductor Corporation (NASDAQ: AMSC) Revenue Rises as Margin Falls Levi Strauss & Co. (NYSE: LEVI) Raises Profit as Wholesale Outruns DTC Stock perps: Cerebras Systems perp's 11.1% drop exceeded several venues' liquidation moves Stock research on every company OptimistFi covers Latest stock research and investment-case updates OptimistFi: evidence-first equity research Sources SEC 8-K earnings release — UnitedHealth Group third quarter 2026 results and guidance update SEC 8-K exhibit 99.2 — Companion earnings release text Read the full OptimistFi thesis on UnitedHealth Group: https://optimistfi.com/stocks/UNH

See what would break the UnitedHealth Group thesis and track it live on the OptimistFi Thesis-Break Engine.

Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.

The full UnitedHealth Group investment case, its status and the next test to watch live on the UnitedHealth Group thesis page.

Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.

UnitedHealth Group Incorporated (NYSE:UNH) on Tuesday posted upbeat third-quarter results.

UnitedHealth Group reported quarterly earnings of $4.69 per share which beat the analyst consensus estimate of $4.15 per share. The company reported quarterly sales of $112.694 billion which beat the analyst consensus estimate of $111.403 billion.

UnitedHealth raised its full-year 2026 adjusted earnings guidance to at least $20.50 per share from its previous range of $19.50 to $20. The revised outlook exceeds the analyst consensus estimate of $19.86.

The company also increased its GAAP earnings forecast to at least $19.50 per share, up from its previous guidance of $18.45 to $18.95. Analysts had expected $18.35 per share.

“Our third quarter results reflect the discipline and execution our teams are bringing to every part of our business, as we continue evolving UnitedHealth Group to deliver a simpler, more supportive experience for patients and the clinicians who care for them,” said Stephen Hemsley, chief executive officer of UnitedHealth Group.

UnitedHealth shares gained 3% to trade at $389.04 on Wednesday.

These analysts made changes to their price targets on UnitedHealth following earnings announcement.

Baird analyst Michael Ha maintained the stock with a Neutral and lowered the price target from $453 to $427.
Barclays analyst Andrew Mok maintained the stock with an Overweight rating and cut the price target from $441 to $440.
Earn 8% APY on a Real Estate-Backed Note from $5,000

EquityMultiple's Alpine Notes have distributed $478M+ with no missed payments. Accredited investors can start with $5,000 at a fixed 8% APY for 6 months.

Considering buying UNH stock? Here’s what analysts think:

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

Key Takeaways UnitedHealth raises 2026 adjusted EPS guidance to at least $20.50, targeting renewed earnings growth in 2027.Elevated commercial medical costs and Medicaid funding gaps remain hurdles despite stabilizing cost trends.Optum Health's earnings rebound and AI expansion support recovery.
UnitedHealth Group Incorporated (UNH - Free Report) outlined improving operating momentum during its third-quarter 2026 earnings call, emphasizing disciplined medical cost management, business modernization and a return to sustainable earnings growth in 2027.

Management raised its full-year earnings outlook while acknowledging persistent commercial medical cost pressures, uneven Medicaid funding and continued investments across Optum.

UNH Raises Outlook and Signals 2027 GrowthChief financial officer Wayne DeVeydt raised the 2026 adjusted earnings guidance to at least $20.50 per share, establishing a stronger earnings base heading into 2027.

DeVeydt said the lower end of UnitedHealth's long-term 13%-16% earnings growth target represents a reasonable starting point for 2027, with current analyst consensus potentially understating the opportunity.

Third-quarter adjusted earnings of $4.69 per share exceeded the Zacks Consensus Estimate of $4.12. Revenues of $112.69 billion surpassed the consensus estimate of $111.38 billion.

UnitedHealth Faces Elevated Commercial CostsUnitedHealthcare CEO Timothy Noel emphasized that commercial medical cost trends remain above the company's initial 11% expectations, reflecting specialty drug expenses, higher clinician costs and No Surprises Act arbitration pressures.

During questioning from UBS, Noel acknowledged that elevated utilization would extend the timeline for achieving long-term commercial margin objectives.

Responding to Bank of America, Noel clarified that management was not seeing medical costs accelerate. Instead, commercial trends were stabilizing, while government programs showed moderation.

UNH Targets Medicare and Medicaid Margin RecoveryBobby Hunter, CEO of Government Programs and Head of Medicare Insurance, told Wolfe Research that Medicare margins should finish 2026 near the upper end of the company's 2%-4% target range.

For 2027, Hunter highlighted growth opportunities in Dual Special Needs Plans, Chronic Special Needs Plans and high-value HMOs. Management continues refining its Medicare Advantage product portfolio while maintaining pricing discipline.

Medicaid CEO Michael Cotton said full-year core Medicaid margins should improve to moderately better than negative 1%. He identified clinical cost management and state funding adjustments as recovery drivers, with a goal of returning to target margins by 2028.

UnitedHealth Advances Optum Health TurnaroundOptum Health generated third-quarter operating earnings of $735 million compared with $41 million a year earlier, reflecting improved medical cost management and operational discipline.

Optum Health CEO Krista Nelson highlighted opportunities in accountable care, home health, hospice and post-acute services. The business remains focused on progressing toward its 6%-8% operating margin target by 2028.

Responding to Barclays, Nelson explained that fourth-quarter performance would reflect normal risk seasonality and additional technology investments. She emphasized that operational improvements achieved during 2026 should continue supporting performance.

UNH Expands Pharmacy and AI OpportunitiesOptum CEO Patrick Conway emphasized integrating pharmacy services with medical care, including specialty pharmacy, behavioral health pharmacy and infusion services.

During JPMorgan's questioning, Chief Growth Officer Jon Mahrt reported specialty pharmacy volume growth of 2.6% despite a broader quarterly volume decline. He also highlighted customer retention in the high 90s within pharmacy benefit management.

Chief Digital and Technology Officer Sandeep Dadlani described Optum Insight's multiyear AI transformation. Its Integrity One platform expanded from two implemented clients at year-end 2025 to 15, with another 24 implementations underway.

UnitedHealth Prioritizes Sustainable ExecutionCEO Stephen Hemsley emphasized restoring financial discipline, simplifying healthcare administration and strengthening relationships with clinicians and consumers.

The company expects AI-enabled processes, integrated value-based care and operational modernization to support productivity and service improvements while positioning its businesses for sustainable growth.

Management plans to provide a more comprehensive 2027 outlook before year-end, including additional clarity on business-level opportunities and investments.

UNH's Zacks Rank and Style Scores SignalUNH currently carries a Zacks Rank #2 (Buy), indicating favorable near-term prospects based on earnings estimate revision trends. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

The stock has a Value Score of A, Growth Score of A, Momentum Score of B and a VGM Score of A. These favorable Style Scores complement its Zacks Rank, reflecting attractive characteristics across valuation, growth and momentum factors.

The combination of a Zacks Rank #2 and strong Style Scores aligns with Zacks' framework for identifying stocks with favorable relative performance potential. However, the Zacks Rank can change as analysts revise earnings estimates following the recently reported results.

UnitedHealth has shed members, slipped 10% in three months, and closed lower on a beat-and-raise quarter. Now a major Wall Street firm is calling for 40% gains, and its argument centers on a business unit most investors are not watching…

UnitedHealth Group (NYSE:UNH | UNH Price Prediction) currently trades at $377.64. Wall Street’s average price target is $480.60, which puts the shares 27.3% below consensus.

UnitedHealth is the largest managed care company in the country. Its UnitedHealthcare insurance arm produces 80% of group revenue, and Optum runs its health services business. The company just beat third-quarter estimates and raised full-year guidance again. The stock still finished the day lower.

Morgan Stanley (NYSE:MS) raised its target from $468 to $529.00 and kept its Overweight rating. That Street-high target means 40.1% upside.

Shrinking Membership Drags UnitedHealth Through a 10% Three-Month Slide
Over three months, UnitedHealth has fallen 10.62%, slipping from $422.63 to $377.76. Shrinking membership is the biggest reason. UnitedHealthcare’s members fell to 48.3 million from 50.1 million a year earlier. Medicare Advantage alone has lost 935,000 members since the start of the year, and employers pulled another 165,000 commercial members in the third quarter.

On earnings day, the stock opened at $397.26, turned, and closed down 0.23%. Adjusted EPS of $4.69 beat the $4.15 consensus. However, revenue fell 0.4% from a year earlier. The medical care ratio improved to 88.4% from 89.9%, but $610 million of positive prior-period reserve development helped get it there.

This weakness is mostly UnitedHealth’s own. Elevance Health (NYSE:ELV) was flat over the same stretch. The company also faces pressure from CMS Star Ratings, Justice Department legal actions over its Medicare business, and Medicaid redeterminations.

Morgan Stanley’s $529 Target Rests on Margin Repair
Morgan Stanley’s thesis has three parts. First, it says that combining UnitedHealthcare with Optum creates a growth loop rivals cannot replicate. Second, it expects medical costs to normalize so margins can return toward historical targets. Third, it expects an aging population to keep driving Medicare Advantage volume.

The quarter backed up parts of that case. Optum Health’s operating earnings rose to $735 million from just $41 million after it left sub-scale value-based care markets. Total operating income grew 52.1%. Full-year adjusted EPS guidance is now at least $20.50, up from $19.50 to $20.00.

Estimates are rising. The 2027 EPS consensus is $22.6102, compared with $20.9705 90 days ago. On forward earnings, the stock trades at about 17x. The company has also bought back more than $5 billion of stock this year.

Of the 26 analysts covering UnitedHealth, 7 give it a Strong Buy, 15 call it a Buy, and 4 recommend Hold. None rate it Sell. Price targets are opinions, though. Morgan Stanley’s case depends on margin gains outpacing membership losses.

UnitedHealth Fell While Its Rivals Held Steady
Elevance was up 0.06% over three months. At $425.41, it sits 6.2% below its $451.71 target. Analysts give it 2 Strong Buy, 12 Buy, and 8 Hold ratings, so the Street sees far less upside than for UnitedHealth.

Cigna Group (NYSE:CI) slipped 2.59% over the past month. At $282.43, its $342.29 target means 21.2% upside. It has 6 Strong Buy, 12 Buy, and 6 Hold ratings, and it trades near 8x forward earnings.

Humana (NYSE:HUM) gained 3.28% over the past month and is up 64.13% this year. At $420.31, it sits 9.8% below its $461.50 target. Its 12 Hold ratings and 1 Sell make it the most divided name in the group.

UnitedHealth has the most analyst-implied upside in the group, whether you use the consensus target or the Street high. That makes its decline look like a story about the company itself.

UnitedHealth Still Leads the S&P 500 This Year
Despite the slide, UnitedHealth is up 16.64% year to date. The S&P 500 is up 14.09% over the same period. Over one year, the stock has gained 8.09%, compared with 17.48% for the index.

At $377.64, the stock is below its $388.46 50-day average and above its $357.79 200-day average. The price also sits well under its 52-week high of $458.79. Across 26 analysts, the consensus target of $480.60 means 27.3% upside. The dividend yields 2.36%.

Earnings Momentum Gives UnitedHealth the Edge
UnitedHealth looks compelling if Optum keeps improving, cost trends stay stable, and EPS estimates keep rising into next year. That path would support a higher multiple. It looks like a value trap if Medicare Advantage keeps losing members, Star Ratings cut bonus payments, or the Justice Department actions lead to penalties. Reserve releases that flattered this quarter’s results would make each of those risks harder to absorb.

I lean bullish. The company raised full-year guidance again this quarter, analysts keep lifting estimates, and the stock trades at about 17x forward earnings. Together, that suggests the market is overweighting membership losses. Still, the case depends on Medicare Advantage enrollment steadying, so watch for the next membership update.

Contact [email protected] for any questions or corrections.

Revenue: $113 billion in Q3 2026.Adjusted EPS: $4.69 in Q3 2026, up from $2.92 a year ago.Consolidated Medical Care Ratio: 88.4% in Q3 2026, compared to 89.9% l

UnitedHealth Group Inc. (NYSE:UNH) beat third-quarter estimates on Tuesday and raised its informal full-year outlook for 2026. Management also told analysts their 2027 numbers look too conservative.

The insurer now expects 2026 adjusted earnings of at least $20.50 per share, up from its previous range of $19.50 to $20. Analysts had expected $19.86, per Benzinga Pro data. 

UNH stock is moving after earnings. See the real-time price action here. Beat on Profit and CostsAdjusted EPS rose about 61% to $4.69 from $2.92 a year earlier, and revenue came in at $112.69 billion against expectations of $111.40 billion.

The medical care ratio fell to 88.4% from 89.9% a year earlier, with UnitedHealth crediting plan design and new pricing for the improvement.

“Our third quarter performance reflects actions taken throughout 2026, driving meaningful progress and reinforcing our confidence to sustainably grow in 2027 and beyond within our 13 to 16% long-term target growth range,” CEO Stephen Hemsley said on the earnings call.

Read Next

A Shot at 2027 ConsensusCFO Wayne DeVeydt went further. “We view our 2026 adjusted EPS guidance of at least $20.50 as a solid run rate on which to grow,” he said.

“We would offer that current analyst consensus for 2027 may understate the opportunity ahead and we see the lower end of our long-term 13% to 16% growth rate as a more reasonable starting point,” DeVeydt added.

Growth of 13% from $20.50 works out to roughly $23.17 per share, while consensus for 2027 sits at $22.62.

Costs Still BiteExecutives did not declare victory on medical costs. “Costs remain stubbornly high across the entire healthcare landscape, in particular in areas such as specialty pharmacy and acute healthcare service intensity,” UnitedHealthcare CEO Tim Noel said.

Noel singled out the No Surprises Act, a law meant to shield patients from unexpected bills. 

“Of particular concern is the ongoing abuse of the No Surprises Act dispute process by a relatively small number of clinician groups and third-party organizations,” he said.

Arbitration awards can run 10 to 11 times what Medicare would pay, he added.

Commercial cost trends are still running above 11%. Asked about margin recovery in the commercial business, Noel said high utilization “is going to stretch out our ability to achieve those long-term objective margins.”

Government programs looked better. The company now expects Medicare Advantage margins near the top of its 2% to 4% range. It called 2026 a trough year for core Medicaid margins, which should come in moderately better than minus 1%.

UnitedHealth shares rose 2% before the bell but reversed after the call opened. Management held back formal 2027 guidance until an investor meeting before year-end.

“So very positive. But we can’t really get to precision at this range,” Hemsley said.

UNH Stock Price Activity: UnitedHealth stock was up 0.58% at $380.71 at the time of publication Tuesday, according to Benzinga Pro.

Read Next

Photo: Piotr Swat / Shutterstock

This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

UnitedHealth Group Incorporated (UNH) Q3 2026 Earnings Call Transcript

NorthCrest Asset Manangement LLC grew its holdings in shares of UnitedHealth Group Incorporated (NYSE:UNH – Free Report) by 41.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 24,897 shares of the healthcare conglomerate’s stock after acquiring an additional 7,273 shares during the quarter. NorthCrest Asset Manangement LLC’s holdings in UnitedHealth Group were worth $9,235,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. General Partner Inc. bought a new position in shares of UnitedHealth Group during the 3rd quarter valued at $512,000. PBCay One RSC Ltd bought a new position in shares of UnitedHealth Group during the first quarter valued at approximately $14,343,000. Lee Johnson Capital Management LLC bought a new stake in shares of UnitedHealth Group during the 2nd quarter valued at about $6,180,000. Kinsale Capital Group Inc. grew its holdings in shares of UnitedHealth Group by 13.4% during the 2nd quarter. Kinsale Capital Group Inc. now owns 38,510 shares of the healthcare conglomerate’s stock worth $16,006,000 after acquiring an additional 4,557 shares during the period. Finally, Fideuram Intesa Sanpaolo Private Banking S.P.A. raised its holdings in UnitedHealth Group by 1,287.2% in the first quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. now owns 60,022 shares of the healthcare conglomerate’s stock worth $16,241,000 after purchasing an additional 55,695 shares in the last quarter. Institutional investors own 87.86% of the company’s stock.

More UnitedHealth Group News Here are the key news stories impacting UnitedHealth Group this week:

Positive Sentiment: Significant earnings beat: Third-quarter net income rose to $4.11 billion, or $4.56 per share, from $2.35 billion, or $2.59 per share, a year earlier. Results exceeded Wall Street expectations by a wide margin. UnitedHealth Charts Continued Turnaround Positive Sentiment: Full-year outlook raised: Management increased its 2026 profit guidance, reinforcing confidence that cost controls and operational improvements can support earnings growth. The company’s previously stated guidance range was $19.50 to $20.00 in adjusted EPS. UnitedHealth Group tops estimates, hikes profit outlook as insurer manages high medical costs Positive Sentiment: Medical-cost trends improved: Spending on medical care, a major pressure point for insurers, showed signs of stabilizing. UnitedHealth also said investments in value-based care and artificial intelligence are beginning to contribute to performance. UnitedHealth Earnings Beat Wall Street Estimates. The Turnaround Continues. Neutral Sentiment: Investor focus remains on execution: Analysts had been watching for top-line growth, insurance margins and guidance after a difficult period for the sector. The latest report offers evidence of recovery, but investors will likely seek confirmation that the gains continue into 2027. UnitedHealth Q3 earnings in focus as investors look for top-line growth Negative Sentiment: Cost risks have not disappeared: UnitedHealth is still managing high medical expenses, leaving the stock sensitive to any renewed deterioration in utilization or insurance margins. Elevated expectations and recent volatility may also limit the immediate upside from the earnings beat. NYSE:UNH opened at $377.98 on Tuesday. UnitedHealth Group Incorporated has a 1-year low of $255.96 and a 1-year high of $461.62. The firm has a market cap of $339.27 billion, a PE ratio of 24.32, a price-to-earnings-growth ratio of 1.43 and a beta of 0.60. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.78 and a quick ratio of 0.78. The company has a 50-day moving average of $388.03 and a 200 day moving average of $381.81. UnitedHealth Group (NYSE:UNH – Get Free Report) last issued its quarterly earnings results on Thursday, July 16th. The healthcare conglomerate reported $6.38 earnings per share for the quarter, beating analysts’ consensus estimates of $4.94 by $1.44. UnitedHealth Group had a net margin of 3.14% and a return on equity of 16.53%. The firm had revenue of $112.03 billion for the quarter, compared to analyst estimates of $110.81 billion. During the same period last year, the company posted $4.08 EPS. UnitedHealth Group’s quarterly revenue was up .4% compared to the same quarter last year. UnitedHealth Group has set its FY 2026 guidance at 19.500-20.000 EPS. As a group, research analysts anticipate that UnitedHealth Group Incorporated will post 19.85 EPS for the current fiscal year.

UnitedHealth Group Dividend Announcement The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 22nd. Shareholders of record on Monday, September 14th were issued a $2.32 dividend. The ex-dividend date was Monday, September 14th. This represents a $9.28 dividend on an annualized basis and a yield of 2.5%. UnitedHealth Group’s dividend payout ratio is presently 59.72%.

Analyst Upgrades and Downgrades Several brokerages have recently weighed in on UNH. Morgan Stanley lifted their price target on UnitedHealth Group from $468.00 to $529.00 and gave the stock an “overweight” rating in a research report on Friday, July 17th. Wall Street Zen raised UnitedHealth Group from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Mizuho upped their price objective on UnitedHealth Group from $470.00 to $493.00 and gave the stock an “outperform” rating in a research note on Monday, July 20th. Bank of America reiterated a “buy” rating and issued a $450.00 price target on shares of UnitedHealth Group in a research report on Monday, July 20th. Finally, Jefferies Financial Group boosted their price target on UnitedHealth Group from $401.00 to $490.00 and gave the stock a “buy” rating in a report on Friday, July 17th. Twenty analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $462.59.

Read Our Latest Stock Analysis on UnitedHealth Group

Insiders Place Their Bets In related news, CEO Patrick Conway sold 1,169 shares of UnitedHealth Group stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $390.00, for a total transaction of $455,910.00. Following the transaction, the chief executive officer owned 15,328 shares in the company, valued at approximately $5,977,920. This trade represents a 7.09% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 0.19% of the stock is owned by company insiders.

UnitedHealth Group Profile (Free Report)

UnitedHealth Group Incorporated (NYSE: UNH) is a diversified health care and well-being company serving individuals, employers, health care providers and government programs. Its operations are organized primarily through UnitedHealthcare and Optum.

UnitedHealthcare provides health benefit plans and services, including employer-sponsored coverage, individual and family plans, Medicare and Medicaid offerings, and other government-supported programs. Its services include health insurance administration, pharmacy benefits and care management.

Optum provides health care services, technology and data solutions, pharmacy services, and analytics to health plans, employers, government agencies, health care providers and consumers.

Read More Five stocks we like better than UnitedHealth Group Salesforce Just Got a Rare Double Upgrade—What Changed? OpenAI’s Revenue Scare Could Be a Big Opportunity for Investors China Still Dominates Rare Earths—These 3 U.S. Companies Could Benefit 3 REITs That May Win in a Higher Interest Rate Environment Want to see what other hedge funds are holding UNH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for UnitedHealth Group Incorporated (NYSE:UNH – Free Report).

Receive News & Ratings for UnitedHealth Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group and related companies with MarketBeat.com's FREE daily email newsletter.

UnitedHealth Group Inc (NYSE:UNH, XETRA:UNH), the US healthcare group, raised its 2026 earnings outlook after third-quarter operating earnings increased 52% to $6.6 billion, supported by lower medical costs and improved operational performance.

The company now expects adjusted earnings of at least $20.50 a share for 2026, up from $18.15 in 2025, following results that exceeded the previous year's performance.

Revenue fell 0.4% to $112.7 billion in the three months to September, while net earnings attributable to shareholders rose to $4.1 billion from $2.3 billion a year earlier.

Adjusted earnings reached $4.69 a share, compared with $2.92 in the third quarter of 2025, while reported earnings increased to $4.56 from $2.59.

The medical care ratio, which measures medical costs as a proportion of premium revenue, improved to 88.4% from 89.9%, partly reflecting medical cost management, pricing discipline and a $610 million favourable reserve adjustment.

The operating cost ratio also declined to 12.8% from 13.5%, reflecting efficiency gains alongside continued investment in technology, administrative processes and patient services.

UnitedHealthcare generated $86.3 billion in revenue and $2.8 billion in operating earnings, while Optum delivered $66.9 billion in revenue and $3.7 billion in operating earnings.

Optum Health remained a mixed picture, with revenue falling 10% to $22.9 billion as the business served fewer patients in markets where its value-based care operations lacked sufficient scale.

However, Optum Health's operating earnings climbed to $735 million from $41 million a year earlier, reflecting tighter operational discipline and medical cost management.

UnitedHealth generated $5.1 billion in operating cash flow during the quarter, while its debt-to-capital ratio stood at 41.7% at the end of September.

The group repurchased $5 billion of shares and paid $6.2 billion in dividends during the first nine months of 2026, as management focused on operational reform and returning to sustainable growth.

3 Healthcare Stocks for 3 Stages of LifeUnitedHealth Group NYSE: UNH reported third-quarter 2026 revenue of $113 billion and adjusted earnings per share of $4.69, compared with $2.92 a year earlier, as the healthcare company cited improving execution across UnitedHealthcare and Optum.

The company’s consolidated medical care ratio was 88.4% in the quarter, improving from 89.9% in the prior-year period. Chief Financial Officer Wayne DeVeydt said the company updated its full-year adjusted EPS outlook to at least $20.50, reflecting third-quarter performance and planned investments during the final months of the year.

Get UnitedHealth Group alerts:

3 Companies That Could Thrive While the Fed Holds Rates SteadyDeVeydt said UnitedHealth repurchased $5 billion of stock through the third quarter and paid $6.2 billion in dividends year to date, with dividends expected to exceed $8 billion for the full year. Its debt-to-capital ratio was 41.7% at quarter-end, and the company said it remains on track to approach 40% by year-end.

Management Targets Growth in 2027 and Beyond Chairman and Chief Executive Officer Steve Hemsley said the company’s actions during 2026 have strengthened its confidence in returning to its long-term adjusted earnings growth target of 13% to 16% beginning in 2027. DeVeydt said the lower end of that range was a “more reasonable starting point” than current analyst consensus estimates for 2027.

MarketBeat Week in Review – 07/27- 07/31Management cited enterprise performance improvements, share repurchases, value-based care gains, and AI-driven modernization as prospective tailwinds. The company also expects to make further investments in policy reforms and modernization, particularly at UnitedHealthcare and Optum Insight, while remaining cautious on medical-cost trends and health-benefit funding pressures.

Hemsley said UnitedHealth is simplifying policies, processes, and technology while seeking to expand integrated, value-based care offerings. He said the company has expanded AI-enabled chart summarization to more than 40% of its employed clinicians, reducing chart-review time by 33%. AI-supported information gathering and research has shortened appeal cycle times by 26%, according to Hemsley.

The company also said it expects to complete all previously announced prior-authorization reforms by year-end. Hemsley said the changes are expected to reduce total prior authorizations by 30%, including a two-thirds reduction for people under age 18.

Medicare and Medicaid Results Improve UnitedHealthcare CEO Tim Noel said Medicare and Medicaid performance showed positive momentum, while the commercial business continued to operate in a difficult but stabilizing cost environment. Demand for care remains elevated, particularly among senior and medically complex populations, he said.

For Medicare Advantage, UnitedHealthcare said it expects to be near the top end of its 2% to 4% margin range in 2026. Bobby Hunter, CEO of Government Programs, attributed the improvement to medical-cost management, recovery actions, and more durable product offerings.

For 2027, UnitedHealthcare plans to prioritize high-value HMO plans, chronic special-needs plans, and dual special-needs plans. The company said more than 94% of Medicare-eligible individuals will have access to a UnitedHealthcare Medicare plan, while about 90% will have access to a Medicare Advantage plan with a $0 premium option.

Hunter said UnitedHealthcare expanded its overall Medicare footprint despite refining some plan offerings, particularly among residual PPO products. He said the company sees growth opportunities in dual special-needs, chronic special-needs, and HMO plans, but will provide formal enrollment guidance later in the year.

The company expects to approach 75% of its Medicare members in plans rated 4 Stars or higher by 2028, compared with what Noel described as a 70% industry average. Hunter said UnitedHealthcare improved nearly every HEDIS and pharmacy-related Stars measure year over year and will continue investing in clinical and pharmacy outcomes.

In Medicaid, CEO Mike Cotton said the company now expects full-year performance to be moderately better than its prior forecasted range. He cited complex-care cost management, network and service curation, member engagement, AI-powered coaching, modernization, and fraud, waste, and abuse efforts.

Still, Cotton said trends remain elevated in behavioral healthcare, specialty pharmacy, home- and community-based services, and inpatient care, though those trends are moderating slightly. UnitedHealthcare expects core Medicaid margins in 2026 to be moderately better than negative 1%, and Cotton said the company aims to return to targeted margins by the end of 2028.

Commercial Costs Remain Elevated UnitedHealthcare said commercial medical-cost trends are still running above its original expectation of 11%. Noel attributed the pressure to higher costs tied to the No Surprises Act, clinician pricing intensity, and expensive specialty drugs.

Noel said arbitration awards under the No Surprises Act’s independent dispute resolution process can approach 6% of total medical spending in some regions. He said the company supports the law’s consumer-protection purpose but is seeking policy changes to address what it considers excessive awards, administrative costs, and dispute volumes.

Management said commercial trends have stabilized but remain well above historical levels. Noel said the company used current utilization and cost information in pricing for 2027 and is not seeing the accelerating trends referenced by one analyst during the call.

Brandon Cuevas, CEO of UnitedHealthcare’s commercial business, said the company had a strong national-account selling season and expects high group retention heading into 2027. He also cited continued strength in its Surest offering and mid-market pipeline.

Optum Emphasizes Value-Based Care, Pharmacy and AI Optum CEO Patrick Conway said Optum Health delivered strong third-quarter performance through a return to value-based care principles, clinical-program execution, and operational improvements. Optum Health reported a 27% year-over-year increase in online self-scheduling and a 10% increase in home-health visits.

Krista Nelson, CEO of Optum Health, said the business serves 20 million patients, including roughly 4 million in fully accountable relationships. She identified further opportunities in professional capitation, shared savings, home health, hospice, surgery centers, and post-acute care programs. The company continues to target an Optum Health margin range of 6% to 8% by 2028.

Nelson said fourth-quarter Optum Health results will reflect normal risk seasonality and further investments in technology and clinician workflows, including AI-enabled care summaries, ambient documentation tools, scheduling, and expanded access capabilities.

At Optum Rx, Conway said more than 50% of membership is now from external, non-UnitedHealthcare customers. Jon Mahrt, CEO of Optum Rx, said client retention is in the high 90% range and that transparency initiatives are supporting sales momentum. He said specialty pharmacy volume rose 2.6% in the quarter, even as total volumes declined 5%.

Optum Insight is investing in healthcare-specific AI products, according to CEO Sandeep Dadlani. He said its Integrity One claims-coding product expanded from two clients at the end of 2025 to 15 implemented clients, with another 24 in implementation. Management said Optum Insight’s remediation work is largely complete and that it expects meaningful progress in 2027, with accelerating growth targeted for 2028 and beyond.

About UnitedHealth Group (NYSE:UNH)UnitedHealth Group Incorporated NYSE: UNH is a diversified health care and well-being company serving individuals, employers, health care providers and government programs. Its operations are organized primarily through UnitedHealthcare and Optum.

UnitedHealthcare provides health benefit plans and services, including employer-sponsored coverage, individual and family plans, Medicare and Medicaid offerings, and other government-supported programs. Its services include health insurance administration, pharmacy benefits and care management.

Optum provides health care services, technology and data solutions, pharmacy services, and analytics to health plans, employers, government agencies, health care providers and consumers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in UnitedHealth Group Right Now?Before you consider UnitedHealth Group, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and UnitedHealth Group wasn't on the list.

While UnitedHealth Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

10.73K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in UNH over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

The $25k Day Trading Barrier is Gone. It's Time to Put Your Capital to Work.

For years, the PDT rule put a major roadblock in front of active traders. The barrier is no longer standing in the way.

But having more freedom doesn't mean every trade is worth taking. 

With Dynamite Day Trading Signals, you'll receive up to 2 options trade alerts per week, each targeting 50%+ gains in a single session.

NO holding positions overnight.

NO waiting weeks for a trade to develop.

Just focused options trades designed to capitalize on opportunities as they emerge.

👉 Get Access to Dynamite Day Trading Signals